Jan 7, 2021 · The stage-modified IPI (SM-IPI) includes 4 risk factors: age greater than 60 years, stage II disease, elevated lactate dehydrogenase, and poor performance status (Eastern Cooperative Oncology Group ≥2). 8 Central nervous system (CNS) prophylaxis was administered by physician preference.

The Revised International Prognostic Index (R-IPI) for Diffuse Large B-cell Lymphoma predicts overall and progression free survival based on risk factors.

Feb 10, 2022 · In the prerituximab era, the Southwest Oncology Group (SWOG) investigators identified age >60 years, stage II disease, elevated lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group (ECOG) performance status (PS) >1 as poor-risk features and developed the stage-modified IPI ([sm-IPI], Table 2). 32 Although 37% had extranodal ...

Jan 11, 2018 · SWOG has defined bulky disease as that in which the largest tumor diameter is ≥10 cm, whereas many groups have used more conservative definitions of 5, 7, or 7.5 cm. Risk assessment may be conducted using sm-IPI, IPI, or age-adjusted IPI.

The SM-IPI was initially described in the landmark SWOG 8736 study in patients treated with CHOP chemotherapy and includes the 4 risk factors: age greater than 60 years, stage II disease, elevated LDH and poor performance status.

May 1, 2015 · Many of the studies regarding surveillance imaging include a broad spectrum of patients, including patients treated in the pre-rituximab era, with variable inclusion criteria including stage and International Prognostic Index (IPI) score.

The original IPI, revised IPI (R-IPI) and NCCN-IPI are prognostic tools used to predict survival in patients with DLBCL. 1. Select score: R-IPI: Revised IPI score re-validated the original IPI score based on patients who received Rituximab based chemotherapy (RCHOP).

The sm-IPI score incorporated the following pretreatment variables: stage II [vs I], age >60 years, elevated serum lactate dehydrogenase (LDH) level, and Eastern Cooperative Oncology Group (ECOG) performance status ≥2.

Jan 7, 2021 · Differences in survival can also be attributed to the presence of unfavorable clinical characteristics that constitute the stage-modified International Prognostic Index (sm-IPI) 2 (age >60 years, elevated lactate dehydrogenase, performance status ≥2, and stage II), bulky disease, and biological heterogeneity.

Mar 31, 2022 · Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model.